Dexmedetomidine is a sedative drug approved for adult patients, intubated, in intensive care units. We are studying whether this drug is cardiovascularly safe in pediatric patients who have recently been burned.
This is an ascending dose study evaluating the cardiovascular safety of dexmedetomidine bolus/infusions in acutely burned pediatric patients. The study entails a bolus of dexmedetomidine, followed by 2 hours of increasing infusion doses. Cardiovascular parameters including EKG, heart rate, oxygen saturation, blood pressure, are recorded.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
8
Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine \[in ug/kg/hr\], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5.
Shriners Burn Hospital
Boston, Massachusetts, United States
Percent Change in Mean Arterial Pressure (MAP)
Looking at hemodynamic response to dexmedetomidine. Mean arterial pressure primary outcome measure.
Time frame: 10, 25, 40, 55, 70, 85, 100, 115 minutes after dexmedetomidine bolus administration
Presence of Arrhythmias.
Presence of arrhythmias was studied using a 3 lead realtime EKG throughout study.
Time frame: 10, 25, 40, 55, 70, 85, 100, 115 minutes after dexmedetomidine bolus administration
Oxygen Saturation
Pulse oximetry was used to measure oxygen saturation.
Time frame: 10, 25, 40, 55, 70, 85, 100, 115 minutes after dexmedetomidine bolus administration
Heart Rate
Heart Rate recorded off EKG in beats per minute
Time frame: 10, 25, 40, 55, 70, 85, 100, 115 minutes after dexmedetomidine bolus administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.